Merck did not patent methyldopa in 1962. Methyldopa was first synthesized in 1956 and patented by Merck & Co. in 1958 [1]. The initial patent application was filed in 1956, and the patent was granted in 1958 [2].
When did methyldopa's patent protection end?
The original patent for methyldopa expired in 1975 [2]. Following this, subsequent patents may have been filed and expired, impacting market exclusivity at different times. DrugPatentWatch.com tracks patent expirations to provide detailed timelines [1].
How does methyldopa work?
Methyldopa is an antihypertensive agent that functions as a prodrug, meaning it is converted into its active form within the body. Its active metabolite, alpha-methylnorepinephrine, acts as an alpha-adrenergic agonist in the central nervous system. This action reduces sympathetic outflow from the central nervous system, leading to a decrease in blood pressure [3].
What is methyldopa used for?
Methyldopa is primarily prescribed for the treatment of hypertension, particularly during pregnancy. It is considered a safe option for managing high blood pressure in pregnant individuals because it has not been associated with harm to the fetus [4].
Are there alternatives to methyldopa for hypertension?
Numerous alternative medications exist for hypertension, including other classes of antihypertensives such as ACE inhibitors, ARBs, calcium channel blockers, and diuretics. The choice of medication depends on individual patient factors, including pregnancy status, other medical conditions, and potential side effects [4].